IPSEN (OTCMKTS:IPSEY) Stock Now Rated “Hold” by Wall Street Analysts

Shares of IPSEN (OTCMKTS:IPSEY) have been assigned a consensus recommendation of “Hold” from the seven brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company.

Several analysts have commented on the stock. Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th.

IPSEN Stock Performance

Shares of OTCMKTS:IPSEY opened at $40.93 on Friday. The business has a fifty day moving average price of $44.76 and a two-hundred day moving average price of $46.22. IPSEN has a 1 year low of $32.68 and a 1 year high of $51.10.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.